US Senate Measure Highlights ‘Warm-Base’ Manufacturing Capacity For Next Pandemic Response
Executive Summary
Committee's bipartisan discussion draft for legislation outlines lessons learned from COVID-19 pandemic response, including need for greater manufacturing facility readiness. Meanwhile, congressional oversight agency calls for “transformation” of response efforts.
You may also be interested in...
Time To End The Myth-Making About COVID Vaccine Reviews
The COVID vaccine development ‘miracle’ is already a core narrative of the pandemic era. But as the US prepares to apply lessons going forward, it is important to recognize the ways the process should not be a model for ‘normal’ operations, especially at FDA.
Senate Pandemic Bill Advances Without Provision Expediting FDA Reviews Based On Foreign Data
Senate committee approves legislation aimed at strengthening the US public health and medical preparedness and response system. Bill includes several provisions impacting FDA but not its 'gold standard' approval process.
Consortium Costs Debated As BARDA, Industry Discuss Plans For Next Pandemic Response
BARDA’s consortium approach scrutinized as industry recovers from US Defense Production Act rated orders. Questions of sustainment fees, interruptible commercial activities explored during BioMaC Industry Day call as agency emphasizes need for proven capacity.